Dr. Benatar is the Walter Bradley Chair of ALS Research at the University of Miami. In addition to ALS, his other clinical and research interest is in myasthenia gravis. He is the principal investigator (PI) of two multi-center clinical trials, one in ALS and one in myasthenia gravis, each funded by the Food & Drug Administration's Orphan Products Development Program. Complementing his clinical trials experience, he has developed a research program focused on the development of novel ALS biomarkers and an exploration of their potential role as outcome measures in clinical trials. To this end, he is the PI of the Pre-symptomatic familial ALS study (Pre-fALS, a prospective observational and biomarker study of people at genetic risk for developing ALS) and the Clinical Research in ALS and Related Disorder for Therapeutic Development (CReATe) Consortium. CReATe, a member of NIH's Rare Diseases Clinical Research Network, is focused on the study of phenotype-genotype relationships and on biomarker development.